Back to Journals » OncoTargets and Therapy » Volume 7

PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis

Authors Liu Y, Jiang Y, Zuo W, Yu K, Shao Z

Received 4 January 2014

Accepted for publication 30 January 2014

Published 10 April 2014 Volume 2014:7 Pages 543—552

DOI https://doi.org/10.2147/OTT.S60115

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Yi-Rong Liu,* Yi-Zhou Jiang,* Wen-Jia Zuo, Ke-Da Yu, Zhi-Ming Shao

Department of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China,

*These authors contributed equally to this publication

Background: Mutations of the p110α catalytic subunit of phosphatidylinositol 3-kinase (PIK3CA) are among the most common genetic aberrations in human breast cancer. At present, controversy exists concerning the prognostic value of the mutations.
Methods: We performed a systematic review and meta-analysis to clarify the association between PIK3CA mutations and survival outcomes. A comprehensive, computerized literature search of PubMed, Web of Science databases, the Chinese Biomedical Literature Database, and Wangfang Data until August 27, 2013 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated by using the fixed effects model or random effects model according to heterogeneity between studies.
Results: Eight eligible studies were included in the analysis, all of which were retrospective cohort studies. The overall meta-analysis demonstrated that the PIK3CA mutations were associated with better clinical outcomes (hazard ratio 0.72; 95% confidence interval: 0.57–0.91; P=0.006). None of the single studies materially altered the original results and no evidence of publication bias was found. Further subgroup analysis of mutations in exons 9 and 20 did not show statistical significance.
Conclusion: PIK3CA mutations in operable primary breast cancer indicate a good prognosis. Further studies should be conducted to investigate the effect of PIK3CA mutations on clinical outcomes in different histologic types, different molecular subtypes of breast cancer, and different exons of PIK3CA.

Keywords: early breast cancer, p110g catalytic subunit of phosphatidylinositol 3-kinase, somatic mutations, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]